CytoDyn (CYDY) News Today $0.23 -0.01 (-2.47%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period CytoDyn Inc (296.SG)March 27 at 11:14 PM | finance.yahoo.comCytoDyn (OTCMKTS:CYDY) Share Price Passes Below Fifty Day Moving Average - Here's WhyCytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average - Should You Sell?March 20, 2025 | marketbeat.comCytoDyn CEO writes March 2025 letter to shareholdersMarch 18, 2025 | markets.businessinsider.comCytoDyn Inc.: March 2025 Letter to ShareholdersMarch 18, 2025 | finanznachrichten.deMarch 2025 Letter to ShareholdersMarch 18, 2025 | globenewswire.comCytoDyn announces survival observations in mTNBC patientsFebruary 25, 2025 | markets.businessinsider.comCytoDyn Inc.: CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | finanznachrichten.deMicro Cap Surging On Company Developed CCR5 Antagonist Showing Promise In PatientsFebruary 24, 2025 | msn.comCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | globenewswire.comCytoDyn Inc. (OTCMKTS:CYDY) Short Interest UpdateCytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 22,639,300 shares, a growth of 6.4% from the January 15th total of 21,272,500 shares. Based on an average trading volume of 11,699,700 shares, the days-to-cover ratio is presently 1.9 days.February 17, 2025 | marketbeat.comCytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | finanznachrichten.deCytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | finanznachrichten.deCytoDyn announces results from preclinical studies with SMCFebruary 6, 2025 | markets.businessinsider.comCytoDyn announces results from preclinical studies with SMCFebruary 6, 2025 | markets.businessinsider.comCytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | globenewswire.comShort Interest in CytoDyn Inc. (OTCMKTS:CYDY) Grows By 15.0%CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 20,123,400 shares, a growth of 15.0% from the December 31st total of 17,499,100 shares. Based on an average trading volume of 6,176,200 shares, the days-to-cover ratio is presently 3.3 days.February 1, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Trading 2.1% Higher - Here's WhyCytoDyn (OTCMKTS:CYDY) Trading Up 2.1% - Time to Buy?January 4, 2025 | marketbeat.comCytoDyn Inc.: December 2024 Letter to ShareholdersDecember 17, 2024 | finanznachrichten.deDecember 2024 Letter to ShareholdersDecember 17, 2024 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Stock Price Up 7.8% - Here's WhyCytoDyn (OTCMKTS:CYDY) Shares Up 7.8% - Here's What HappenedDecember 14, 2024 | marketbeat.comCytoDyn Inc. (CYDY) Stock Price, News, Quote & History - Yahoo FinanceDecember 11, 2024 | finance.yahoo.comFormer Portland area biotech CEO is convicted in securities fraud schemeDecember 11, 2024 | bizjournals.comCytoDyn CEOs Caught in Fraud Scheme to Inflate Stock PricesDecember 11, 2024 | msn.comCytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in OncologyNovember 25, 2024 | markets.businessinsider.comCytoDyn Inc. (OTCMKTS:CYDY) Sees Large Growth in Short InterestCytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 16,577,600 shares, a growth of 25.8% from the October 15th total of 13,179,400 shares. Based on an average trading volume of 6,265,900 shares, the days-to-cover ratio is presently 2.6 days.November 16, 2024 | marketbeat.comCytoDyn Announces FDA Clearance of Its Phase II Oncology TrialNovember 4, 2024 | globenewswire.comCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC LaboratoriesOctober 30, 2024 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Shares Down 4% - Should You Sell?CytoDyn (OTCMKTS:CYDY) Stock Price Down 4% - What's Next?October 22, 2024 | marketbeat.comCytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical DevelopmentOctober 8, 2024 | finance.yahoo.comCytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesOctober 7, 2024 | finance.yahoo.comCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesOctober 7, 2024 | globenewswire.comCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology TrialOctober 4, 2024 | globenewswire.comCytoDyn Announces Preliminary Findings in Study with SMC LaboratoriesSeptember 24, 2024 | globenewswire.comSeptember 2024 Letter to ShareholdersSeptember 9, 2024 | globenewswire.comCytoDyn Inc. (OTCMKTS:CYDY) Sees Significant Growth in Short InterestCytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 10,797,300 shares, a growth of 25.3% from the July 31st total of 8,617,700 shares. Based on an average daily volume of 6,688,300 shares, the days-to-cover ratio is currently 1.6 days.August 30, 2024 | marketbeat.comCytoDyn Engages Leading CRO For Phase II Inflammation TrialAugust 23, 2024 | globenewswire.comCytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal CancerAugust 12, 2024 | globenewswire.comCytoDyn Announces Settlement with Amarex Clinical Research LLCJuly 9, 2024 | globenewswire.comCytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024June 27, 2024 | globenewswire.comCytoDyn to Host Webcast to Provide Company UpdateMay 28, 2024 | globenewswire.comMay 2024 Letter to ShareholdersMay 16, 2024 | globenewswire.comCytoDyn Inc. (OTCMKTS:CYDY) Sees Large Decline in Short InterestCytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 4,724,300 shares, a drop of 25.2% from the January 31st total of 6,311,900 shares. Based on an average daily trading volume, of 5,725,000 shares, the short-interest ratio is currently 0.8 days.March 3, 2024 | marketbeat.comCytoDyn Says FDA Lifts Hold On LeronlimabFebruary 29, 2024 | markets.businessinsider.comFDA lifts clinical hold on CytoDyn drug, stock rallies 22%February 29, 2024 | msn.comCytoDyn Announces FDA Has Lifted Clinical HoldFebruary 29, 2024 | globenewswire.comCytoDyn Inc CYDYFebruary 10, 2024 | morningstar.comCytoDyn Submits Revised HIV Clinical Trial Protocol To FDA, Starts Glioblastoma Pre-Clinical StudyFebruary 1, 2024 | markets.businessinsider.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaFebruary 1, 2024 | finance.yahoo.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaFebruary 1, 2024 | tmcnet.comInvestors file another lawsuit against CytoDynJanuary 31, 2024 | bizjournals.com Remove Ads Get CytoDyn News Delivered to You Automatically Sign up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Media Mentions By Week CYDY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYDY News Sentiment▼0.370.78▲Average Medical News Sentiment CYDY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYDY Articles This Week▼10▲CYDY Articles Average Week Remove Ads Get CytoDyn News Delivered to You Automatically Sign up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVTCY News Today GYRE News Today AUPH News Today ADPT News Today SYRE News Today SNDX News Today SPRY News Today NRIX News Today ELVN News Today NTLA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYDY) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
